item management s discussion and analysis of financial condition and results of operations the following discussion contains  in addition to historical information  forward looking statements within the meaning of section a of the securities act of  as amended  and section e of the securities and exchange act of  as amended  which represent the company s expectations or beliefs 
when used in this report  the words may  could  should  would  believe  anticipate  estimate  expect  intend  plan and similar expressions are intended to identify forward looking statements 
these statements by their nature involve substantial risks and uncertainties  certain of which are beyond the company s control 
the company cautions that various factors  including the factors described in the company s filings with the securities and exchange commission  as well as general economic conditions  changes in applicable laws and regulations  industry trends  a dependence upon and or loss of key employees  vendors or customers  the loss of strategic product shipping relationships  customer demand  product availability  competition including pricing and availability  concentrations of credit risks  distribution efficiencies  capacity constraints and technological difficulties could cause actual results or outcomes to differ materially from those expressed in any forward looking statements of the company 
any forward looking statement speaks only as of the date of this report and the company undertakes no obligation to update any forward looking statement or statements to reflect events or circumstances after the date on which such statements are made or to reflect the occurrence of an unanticipated event 
new factors emerge from time to time  and it is not possible for the company to predict all of such factors 
further  the company cannot assess the impact of each such factor on its business or the extent to which any factor  or combination of factors  may cause actual results to differ materially from those contained in any forward looking statements 
results of operations net sales and operating income loss 
the following table sets forth the net sales and operating income loss for each segment of the company s business for the last three fiscal years year ended march  net sales waste management services segment   consumer healthcare products segment    company totals    operating income loss waste management services segment    consumer healthcare products segment    corporate    company totals    fiscal vs 
fiscal the company s net sales increased by to  for the year ended march   from  for the year ended march  the company s operating income increased to  for the year ended march   from  for the year ended march  the company s cost of goods sold increased to of net sales for the year ended march   from of net sales for the year ended march  the company s selling  general  and administrative expenses increased to of net sales for the year ended march   from of net sales for the year ended march  the results of operations of the company are dependent upon the results of operations of each of its subsidiaries operating in the individual business segments 
set forth below is a discussion of the results of operations of each of these segments 
waste management services segment net sales in the company s waste management services segment  which operates through bio systems  increased to  for the year ended march   from  for the year ended march  the sales growth is primarily due to securing new hospital contracts for bio systems core business of providing sharps sharp edged medical waste such as scalpels  syringes  and needles disposal services which utilize cost effective reusable containers and price increases initiated for contract renewals 
additionally  the industry trend toward the formation of hospital networks and bio systems success in marketing its services to these networks have enhanced bio systems sales and market share growth 
bio systems operating income increased to  for the year ended march   from  for the year ended march  bio systems cost of goods sold increased to of its net sales for the year ended march   from of net sales for the year ended march  cost of goods sold is primarily comprised of direct labor and related costs and benefits to collect and process waste amounting to of net sales  vehicle and equipment maintenance  repair  capital lease financing  and depreciation amounting to of net sales  waste disposal costs amounting to of net sales  and warehouse expenses amounting to of net sales 
selling  general  and administrative expenses as a percentage of bio systems net sales increased to for the year ended march   from for the year ended march  selling  general  and administrative expenses are primarily comprised of management  administrative and office compensation  related costs and benefits  and utilities  insurance  property taxes  depreciation  bad debt  professional fees  rent  amortization  advertising promotion  travel and miscellaneous other expenses 
starting early in the year ended march  and continuing through the year ended march   bio systems has had substantial new hospital activity 
preparing new accounts for service requires  among other things  installation of bio systems reusable containers and sometimes considerable operational follow up which causes temporary increases in certain costs and expenses with respect to those accounts 
additionally  bio systems operating payroll and transportation costs and expenses have increased due to the addition of personnel and medical waste transportation vehicles needed to service the new hospital accounts 
consumer healthcare products segment net sales for scherer labs  which operates in the company s consumer healthcare products segment  increased to  for the year ended march   from  for the year ended march  the increase in scherer labs net sales is due primarily to the following factors i the general increase in the level of business for the year ended march   ii extension of the contract with wal mart  and iii the addition of cvs corporation s southeastern stores initially selling just one of scherer lab s products 
scherer labs operating income increased to  for the year ended march   from  for the year ended march  scherer labs cost of goods sold increased slightly to of its net sales for the year ended march   from for the year ended march  cost of goods sold is primarily comprised of the cost of materials for products the company distributes and the related shipping expenses 
selling  general  and administrative expenses increased to of net sales for the year ended march   from for the year ended march  selling  general  and administrative expenses are primarily comprised of management  administrative and office compensation  related costs and benefits  and utilities  insurance  property taxes  depreciation  bad debt  professional fees  rent  amortization  advertising promotion  travel and miscellaneous other expenses 
corporate the company s operating expenses at the corporate level increased to  for the year ended march   from  for the year ended march  certain administrative  accounting  management oversight  and payroll services are performed by the company s corporate office for its subsidiaries 
the corporate operating expenses primarily include the salaries  wages and related benefits of the personnel who perform these functions including the company s executive officers  rent expense  professional  accounting and legal fees 
salaries and wages decreased from  for the year ended march   to  for the year ended march  this decrease was partially due to one fewer employee and offset by the increase of  for outside clerical services 
the company did not incur any lawsuit settlement expenses in the year ended march   versus  for the year ended march    of which was accounted for in bio systems 
professional  accounting and legal fees increased from  for the year ended march   to  for the year ended march  fiscal vs 
fiscal the company s net sales increased by to  for the year ended march   from  for the year ended march  the company s operating income decreased to  for the year ended march   from  for the year ended march  the company s cost of goods sold increased slightly to of net sales for the year ended march   from of net sales for the year ended march  the company s selling  general  and administrative expenses  including litigation settlements  were unchanged at of net sales for the years ending march  and the results of operations of the company are dependent upon the results of operations of each of its subsidiaries operating in the individual business segments 
set forth below is a discussion of the results of operations of each of these segments 
waste management services segment net sales in the company s waste management services segment  which operates through bio systems  increased to  for the year ended march   from  for the year ended march  as in the past few years  the sales growth is primarily due to securing new hospital contracts for bio systems core business of providing sharps disposal services which utilize cost effective reusable containers 
bio systems operating income decreased to  for the year ended march   from  for the year ended march  bio systems cost of goods sold increased to of its net sales for the year ended march   from of net sales for the year ended march  selling  general  and administrative expenses as a percentage of bio systems net sales were unchanged at of net sales for the years ending march  and starting early in the year ended march   and continuing through the year ended march   bio systems has had substantial new hospital activity 
preparing new accounts for service requires  among other things  installation of bio systems reusable containers and sometimes considerable operational follow up which causes temporary increases in certain costs and expenses with respect to those accounts 
additionally  bio systems operating payroll and transportation costs and expenses have increased due to the additions of personnel and medical waste transportation vehicles needed to service the new hospital accounts 
as a result of the increase in net sales  bio systems has had better absorption of the costs and expenses associated with the new account installations and service for the year ended march   compared to prior years 
consumer healthcare products segment net sales for scherer labs  which operates in the company s consumer healthcare products segment  increased to  for the year ended march   from  for the year ended march  the increase in scherer labs net sales is due primarily to the following factors i the general increase in the level of business in fiscal year and ii a new contract with wal mart 
through mckesson  its primary distributor  scherer labs began selling the ero earwax removal system to wal mart in the first quarter of the year ended march  sales of this product to wal mart during the year ended march   were approximately  or of gross sales for the segment for the year 
as a result of the increase in net sales  scherer labs operating income increased to  for the year ended march   from  for the year ended march  scherer labs cost of goods sold increased slightly to of its net sales for the year ended march   from for the year ended march  and its selling  general  and administrative expenses decreased to of net sales for the year ended march   from for the year ended march  corporate the company s operating expenses in the corporate level increased to  for the year ended march   from  for the year ended march  certain administrative  accounting  management oversight and payroll services are performed by the company s corporate office 
the corporate operating expenses include the salaries and wages of the personnel who perform these functions including the company s executive officers  rent expense  and professional accounting and legal fees 
payroll expense at the corporate level decreased for the year ending march   as compared to the year ended march  these payroll reductions will be offset in the year ended march   because as of april   the company began paying a salary to robert p 
scherer  jr  the company s chairman of the board  president and chief executive officer 
in the year ended march   and in prior years  the company did not pay mr 
scherer any salary or other compensation for his services 
the company also accrued expense of  in the year ended march   to settle a lawsuit that was pending at the end of the year ended march  other income expense 
the company recorded interest income of   and  in the years ending march   and  respectively 
the increase in interest income is a result of the investment of the company s cash  principally in marketable securities 
during the year ended march   the company recognized equity in net losses of unconsolidated companies of  relating to its equity method investments in econometrics  inc  compliance  inc  protocol  llc  and medicarefacts  llc 
in the fourth quarter of the year ended march   the company wrote off the remaining balance of  of its investment in protocol  llc 
the company also recognized a  impairment charge in the quarter ended december   relating to a write down of renaissance pharmaceuticals  inc  an investment recorded under the cost method of accounting see note of notes to consolidation financial statement included elsewhere herein 
income taxes 
the company recorded an income tax provision benefit of   and  for the years ending march   and  respectively 
for the year ended march   based on its recent earnings history  no asset valuation allowance is necessary versus  for the year ended march  this  combined with  of other taxes  net  resulted in the  of income tax benefit at march  for the year ended march   and in prior years  the company utilized tax loss carryforwards to offset taxable income 
additionally  in the year ended march   the company eliminated its valuation allowance against deferred tax assets due to the favorable resolution of uncertainties that were outstanding as of march  quarterly results of operations the following table presents certain unaudited quarterly statement of operations data for each of the last quarters through the quarter ended march  the information has been derived from the company s unaudited consolidated financial statements 
in the opinion of management  the unaudited financial statements have been prepared on a basis consistent with the financial statements which appear elsewhere in this form k and include all adjustments  consisting only of normal recurring adjustments  necessary for a fair statement of the financial position and results of operations for such unaudited periods 
historical results are not necessarily indicative of results to be expected in the future 
quarterly results of operations in thousands except per share data fiscal year ended march  fiscal year ended march  fiscal year ended march  june sept dec mar june sept dec mar june sept dec mar net sales       cost of sales       gross margin       selling  general  and administrative expenses   litigation expense operation income loss other income expense interest income equity in net losses of unconsolidated companies impairment charge for other investments  at cost other  net total other income expense income before income taxes provision benefit for income taxes net income basic net income per common share diluted income per common share 
weighted average common shares outstanding basic   weighted average common shares outstanding diluted   liquidity and capital resources the company s cash and cash equivalents totaled  at march   an increase of  from march  since march   the company has made additional investments of  in econometrics  inc and  in compliance inc 
in october  the company made an investment of  in medicarefacts  llc 
also  since march   the company has sold  of marketable securities which increased cash and cash equivalents 
the company s working capital increased to  at march   from  at march  this increase was primarily for the reasons described below and the result of investment transactions described above 
cash flows from operating activities 
the company s cash provided by operating activities from continuing operations totaled  for the year ended march   as compared to  for the year ended march  the increase at march   is primarily due to increased sales of  at bio systems and scherer labs 
cash flows from investing and financing activities 
the company s investing activities used cash of   and  for the years ending march   and  respectively 
during the year ended march   the company received proceeds of  from the sale of its investments in marketable securities 
during the years ending march  and  the company increased its investment in marketable securities by  and  respectively  when it made additional investments in fixed income government bonds 
the company s marketable securities are composed of municipal bonds  corporate bonds and preferred stocks and mature over periods ranging from years to years see note of the notes to consolidated financial statements included elsewhere herein 
during the year ended march   the company made additional investments in unconsolidated companies  accounted for using the equity method  of  in econometrics  inc   in compliance  inc  and  in medicarefacts  llc 
during the year ended march   the company made cash investments of  in econometrics  inc   in protocol  llc  and  in compliance  inc see note of notes to consolidated financial statements included elsewhere herein 
as a result of the growth in business  bio systems made capital expenditures for vehicles  equipment  and containers of   and  in the years ending march    and  respectively 
cash provided by the company s financing activities was  for the year ended march   caused by capital lease financing of new vehicles 
cash flows used in financing activities were  and  in the years ending march  and  respectively  when the company paid off certain capital leases 
management of the company believes that its current cash on hand and its current cash flow is sufficient to maintain operations on a short term and long term basis 
the company continues to evaluate its long term options with regard to the use of its remaining cash on hand including possible investment and acquisition opportunities 
item a 
quantitative and qualitative disclosures about market risk none 

